Literature DB >> 11483629

Cholesterol crystallization in model biles: effects of bile salt and phospholipid species composition.

A Moschetta1, G P vanBerge-Henegouwen, P Portincasa, G Palasciano, K J van Erpecum.   

Abstract

Cholesterol in human bile is solubilized in micelles by (relatively hydrophobic) bile salts and phosphatidylcholine (unsaturated acyl chains at sn-2 position). Hydrophilic tauroursodeoxycholate, dipalmitoyl phosphatidylcholine, and sphingomyelin all decrease cholesterol crystal-containing zones in the equilibrium ternary phase diagram (van Erpecum, K. J., and M. C. Carey. 1997. Biochim. Biophys. Acta. 1345: 269-282) and thus could be valuable in gallstone prevention. We have now compared crystallization in cholesterol-supersaturated model systems (3.6 g/dl, 37 degrees C) composed of various bile salts as well as egg yolk phosphatidylcholine (unsaturated acyl chains at sn-2 position), dipalmitoyl phosphatidylcholine, or sphingomyelin throughout the phase diagram. At low phospholipid contents [left two-phase (micelle plus crystal-containing) zone], tauroursodeoxycholate, dipalmitoyl phosphatidylcholine, and sphingomyelin all enhanced crystallization. At pathophysiologically relevant intermediate phospholipid contents [central three-phase (micelle plus vesicle plus crystal-containing) zone], tauroursodeoxycholate inhibited, but dipalmitoyl phosphatidylcholine and sphingomyelin enhanced, crystallization. Also, during 10 days of incubation, there was a strong decrease in vesicular cholesterol contents and vesicular cholesterol-to-phospholipid ratios (approximately 1 on day 10), coinciding with a strong increase in crystal mass. At high phospholipid contents [right two-phase (micelle plus vesicle-containing) zone], vesicles were always unsaturated and crystallization did not occur. Strategies aiming to increase amounts of hydrophilic bile salts may be preferable to increasing saturated phospholipids in bile, because the latter may enhance crystallization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483629

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Role of nucleation of bile liquid crystal in gallstone formation.

Authors:  Hai-Ming Yang; Jie Wu; Jin-Yi Li; Lin Gu; Min-Fei Zhou
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

Review 2.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

3.  Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.

Authors:  I J A M Jonkers; A H M Smelt; M Ledeboer; M E Hollum; I Biemond; F Kuipers; F Stellaard; R Boverhof; A E Meinders; C H B W Lamers; A A M Masclee
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  Microarray analysis of hepatic gene expression in gallstone-susceptible and gallstone-resistant mice.

Authors:  Patricia A Dyck; Farzana Hoda; Elizabeth S Osmer; Richard M Green
Journal:  Mamm Genome       Date:  2003-09       Impact factor: 2.957

5.  Protective effect of Glechoma hederacea extract against gallstone formation in rodent models.

Authors:  Min Xiao; Mengbi Yang; Xiaoyu Ji; Dan Li; Yuning Xie; Yuanfeng Lyu; Zhong Zuo
Journal:  BMC Complement Med Ther       Date:  2021-07-14

6.  Telocytes: new insight into the pathogenesis of gallstone disease.

Authors:  Andrzej Matyja; Krzysztof Gil; Artur Pasternak; Krystyna Sztefko; Mariusz Gajda; Krzysztof A Tomaszewski; Maciej Matyja; Jerzy A Walocha; Jan Kulig; Piotr Thor
Journal:  J Cell Mol Med       Date:  2013-04-04       Impact factor: 5.310

7.  Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study.

Authors:  Tao Wu; Zhigang Zhang; Bin Liu; Dezhi Hou; Yun Liang; Jie Zhang; Peng Shi
Journal:  BMC Genomics       Date:  2013-10-01       Impact factor: 3.969

8.  Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model.

Authors:  Motoko Kuba; Takashi Matsuzaka; Rie Matsumori; Ryo Saito; Naoko Kaga; Hikari Taka; Kei Ikehata; Naduki Okada; Takuya Kikuchi; Hiroshi Ohno; Song-Iee Han; Yoshinori Takeuchi; Kazuto Kobayashi; Hitoshi Iwasaki; Shigeru Yatoh; Hiroaki Suzuki; Hirohito Sone; Naoya Yahagi; Yoji Arakawa; Tsutomu Fujimura; Yoshimi Nakagawa; Nobuhiro Yamada; Hitoshi Shimano
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.